AI assistant
Salarius Pharmaceuticals, Inc. — Director's Dealing 2015
Jan 29, 2015
35494_dirs_2015-01-28_06b18416-8c53-42ae-908b-8413453597cc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Flex Pharma, Inc. (FLKS)
CIK: 0001615219
Period of Report: 2015-01-28
Reporting Person: HUTT PETER BARTON (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $0.60 | 2024-04-08 | Common Stock (28021) | Direct | |
| Stock Option (right to buy) | $4.28 | 2024-10-14 | Common Stock (7005) | Direct | |
| Series A Preferred Stock | $0.00 | Common Stock (50000) | Direct |
Footnotes
F1: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "2014 Plan"). 25% of the total shares underlying this option vest on April 9, 2015 the remaining shares vest 1/48 per month over the next 36 months thereafter, subject to continued service to the Issuer through each vesting date.
F2: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "2014 Plan"). 25% of the total shares underlying this option vest on April 9, 2015 the remaining shares vest 1/48 per month over the next 36 months thereafter, subject to continued service to the Issuer through each vesting date.
F3: N/A.
F4: The shares have no expiration date.
F5: The shares will automatically convert on a 4.2528-for-1 basis into shares of the Issuer's Common Stock immediately upon the closing of a Qualified Public Offering (as defined in the Amended and Restated Certificate of Incorporation) as filed with the State of Delaware.